XenoPort, Inc.
28
0
0
24
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
3.6%
1 terminated/withdrawn out of 28 trials
96.0%
+9.5% vs industry average
36%
10 trials in Phase 3/4
50%
12 of 24 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (28)
A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
Role: collaborator
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Role: lead
An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
Role: lead
Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome (RLS) Post Marketing Commitment Study
Role: lead
An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects
Role: lead
A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS
Role: lead
A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers
Role: lead
An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD
Role: lead
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
Role: lead
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
Role: lead
A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
Role: lead
A Safety and Efficacy Study of XP19986 in Subjects With Spasticity Due to Spinal Cord Injury
Role: lead
A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects
Role: lead
Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome
Role: collaborator
Simulated Driving Study in Restless Legs Syndrome
Role: lead
A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
Role: lead
XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.
Role: lead
A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)
Role: lead
Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome
Role: lead
XP13512 vs. Placebo in Patients With Restless Legs Syndrome.
Role: lead